The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis.
Amyloidosis
Cardiac
Overall survival
Prognosis
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
26
08
2020
accepted:
05
07
2021
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
ppublish
Résumé
To retrospectively identify the critical characteristics and prognostic factors of light-chain amyloidosis. Data were collected and compared from 91 patients who were diagnosed with light-chain amyloidosis at four hospitals between January 2010 and November 2018. We analyzed the clinical characteristics and performed an overall survival (OS) analysis. Patients (median age, 60 years) were diagnosed with organ involvement of the kidney (91.2%), heart (56%), liver (14.3%), soft tissue (18.7%), or gastrointestinal tract (15.4%), and 68.1% of patients had more than two organs involved. Patients were most treated with bortezomib-based regimens (56%), and only one patient had autologous stem cell transplantation (auto-ASCT). The median OS was 36.33 months and was influenced by the ECOG score, renal involvement, cardiac involvement, hepatic involvement, and persistence of positive immunofixation. Patients who received bortezomib-based treatment had a trend of favorable OS compared to those who received non-bortezomib-based treatments, but the difference was not statistically significant. Although the overall number of organs involved was not related to OS, the number of organs involved in the heart, liver and kidney was related. Multivariate analysis indicated that cardiac involvement and negative hematologic response with persistence of positive immunofixation were independent prognostic factors for OS. Cardiac involvement and the hematologic response to treatment were independent prognostic factors for OS in light-chain amyloidosis patients.
Identifiants
pubmed: 35747578
doi: 10.1007/s12288-021-01469-y
pii: 1469
pmc: PMC9209627
doi:
Types de publication
Journal Article
Langues
eng
Pagination
444-453Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare no conflict of interest.
Références
Expert Rev Hematol. 2018 Feb;11(2):117-127
pubmed: 29307226
Amyloid. 2011 Jun;18 Suppl 1:92-3
pubmed: 21838445
J Clin Oncol. 2004 Sep 15;22(18):3751-7
pubmed: 15365071
Acta Haematol. 2015;133(4):336-46
pubmed: 25531398
Curr Hematol Malig Rep. 2020 Jun;15(3):155-167
pubmed: 32394186
Indian J Hematol Blood Transfus. 2018 Apr;34(2):216-226
pubmed: 29622862
Blood. 2014 Oct 9;124(15):2325-32
pubmed: 25115890
Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H95-103
pubmed: 23624626
Eur J Haematol. 2016 Oct;97(4):342-7
pubmed: 26773409
Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):56-61
pubmed: 20223730
N Engl J Med. 2003 Aug 7;349(6):583-96
pubmed: 12904524
Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):104-10
pubmed: 26752455
Circ J. 2019 Mar 25;83(4):775-782
pubmed: 30773521
Am J Hematol. 2013 Jan;88(1):52-5
pubmed: 23027340
Blood. 2015 Apr 2;125(14):2239-44
pubmed: 25636337
Blood Cancer J. 2018 Nov 5;8(11):101
pubmed: 30397193
Am J Hematol. 2005 Aug;79(4):319-28
pubmed: 16044444
Blood Cancer J. 2018 May 23;8(5):44
pubmed: 29795248
Semin Hematol. 1995 Jan;32(1):45-59
pubmed: 7878478
Int J Hematol. 2015 Aug;102(2):200-4
pubmed: 26016720
Blood. 2016 Jul 14;128(2):159-68
pubmed: 27053535
Amyloid. 2011 Jun;18 Suppl 1:80-2
pubmed: 21838441
Ann Med. 2017 Nov;49(7):545-551
pubmed: 28271734